Born out of the lab of Professor Patrick Gunning at the University of Toronto, a serial entrepreneur with a successful track record, HDAX Therapeutics was created with a foundation in translational science and a mission to advance revolutionary treatments.
Our entrepreneurial drug developers have built the technology behind HDAX from a mere concept into distinct programs with therapeutical potential in neurology, cardiometabolic diseases and more. HDAX is well-charged with an extensive network, profound passion and unwavering tenacity to transform therapeutic outcomes for patients.